Regenxbio (RGNX) Downgraded by BidaskClub
BidaskClub cut shares of Regenxbio (NASDAQ:RGNX) from a buy rating to a hold rating in a report published on Friday morning.
Several other analysts have also commented on the stock. Zacks Investment Research raised shares of Regenxbio from a hold rating to a strong-buy rating and set a $38.00 price target for the company in a research report on Wednesday, October 18th. Morgan Stanley reissued an overweight rating and set a $34.00 price target on shares of Regenxbio in a research report on Thursday, November 9th. Raymond James Financial reissued a buy rating on shares of Regenxbio in a research report on Friday, January 5th. Barclays initiated coverage on shares of Regenxbio in a research report on Wednesday, November 22nd. They set an overweight rating and a $38.00 price target for the company. Finally, Bank of America reissued a buy rating and set a $38.00 price target (up from $33.00) on shares of Regenxbio in a research report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Regenxbio currently has a consensus rating of Buy and a consensus price target of $42.43.
Shares of Regenxbio (NASDAQ RGNX) opened at $24.80 on Friday. The company has a market cap of $772.40, a PE ratio of -9.19 and a beta of -1.30. Regenxbio has a 1 year low of $16.30 and a 1 year high of $36.45.
In other news, SVP Curran Simpson sold 2,000 shares of the company’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $29.31, for a total transaction of $58,620.00. Following the transaction, the senior vice president now owns 41,500 shares in the company, valued at $1,216,365. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $27.71, for a total transaction of $277,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,000 shares of company stock worth $2,879,096. Corporate insiders own 17.00% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of RGNX. Legal & General Group Plc increased its holdings in shares of Regenxbio by 41.4% during the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 2,011 shares in the last quarter. Ardsley Advisory Partners acquired a new position in shares of Regenxbio during the second quarter valued at about $197,000. Voya Investment Management LLC acquired a new position in shares of Regenxbio during the second quarter valued at about $249,000. Asymmetry Capital Management L.P. increased its holdings in shares of Regenxbio by 12.2% during the second quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 1,508 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Regenxbio by 1.1% during the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 68.69% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Regenxbio (RGNX) Downgraded by BidaskClub” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://theolympiareport.com/2018/02/05/regenxbio-rgnx-downgraded-by-bidaskclub.html.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.